List of Contents

Homecare Diagnostics and Therapeutics Market Size, Share, and Trends 2024 to 2034

The global homecare diagnostics & therapeutics market size is calculated at USD 249.93 billion in 2024, grew to USD 269.92 billion in 2025, and is predicted to hit around USD 539.57 billion by 2034, expanding at a CAGR of 8% between 2024 and 2034.

  • Last Updated : October 2024
  • Report Code : 1476
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Homecare Diagnostics and Therapeutics Market 

5.1. COVID-19 Landscape: Homecare Diagnostics and Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Homecare Diagnostics and Therapeutics Market, By Product

8.1. Homecare Diagnostics and Therapeutics Market, by Product Type, 2024-2034

8.1.1. Diagnostics

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Therapeutics

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Mobility Care Products

8.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Homecare Diagnostics and Therapeutics Market, By Service

9.1. Homecare Diagnostics and Therapeutics Market, by Service, 2024-2034

9.1.1. Rehabilitation Therapy Services

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Skilled Nursing Services

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Respiratory Therapy Services

9.1.3.1. Market Revenue and Forecast (2021-2034)

9.1.4. Pregnancy Care Services

9.1.4.1. Market Revenue and Forecast (2021-2034)

9.1.5. Infusion Therapy Services

9.1.5.1. Market Revenue and Forecast (2021-2034)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Homecare Diagnostics and Therapeutics Market, By Indication 

10.1. Homecare Diagnostics and Therapeutics Market, by Indication, 2024-2034

10.1.1. Cardiovascular Disorders

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Cancer

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Diabetes

10.1.3.1. Market Revenue and Forecast (2021-2034)

10.1.4. Respiratory Diseases

10.1.4.1. Market Revenue and Forecast (2021-2034)

10.1.5. Wound Care

10.1.5.1. Market Revenue and Forecast (2021-2034)

10.1.6. Others

10.1.6.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Homecare Diagnostics and Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2021-2034)

11.1.2. Market Revenue and Forecast, by Service (2021-2034)

11.1.3. Market Revenue and Forecast, by Indication (2021-2034)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.1.4.2. Market Revenue and Forecast, by Service (2021-2034)

11.1.4.3. Market Revenue and Forecast, by Indication (2021-2034)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.1.5.2. Market Revenue and Forecast, by Service (2021-2034)

11.1.5.3. Market Revenue and Forecast, by Indication (2021-2034)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.2. Market Revenue and Forecast, by Service (2021-2034)

11.2.3. Market Revenue and Forecast, by Indication (2021-2034)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.4.2. Market Revenue and Forecast, by Service (2021-2034)

11.2.4.3. Market Revenue and Forecast, by Indication (2021-2034)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.5.2. Market Revenue and Forecast, by Service (2021-2034)

11.2.5.3. Market Revenue and Forecast, by Indication (2021-2034)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.6.2. Market Revenue and Forecast, by Service (2021-2034)

11.2.6.3. Market Revenue and Forecast, by Indication (2021-2034)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.7.2. Market Revenue and Forecast, by Service (2021-2034)

11.2.7.3. Market Revenue and Forecast, by Indication (2021-2034)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.2. Market Revenue and Forecast, by Service (2021-2034)

11.3.3. Market Revenue and Forecast, by Indication (2021-2034)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.4.2. Market Revenue and Forecast, by Service (2021-2034)

11.3.4.3. Market Revenue and Forecast, by Indication (2021-2034)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.5.2. Market Revenue and Forecast, by Service (2021-2034)

11.3.5.3. Market Revenue and Forecast, by Indication (2021-2034)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.6.2. Market Revenue and Forecast, by Service (2021-2034)

11.3.6.3. Market Revenue and Forecast, by Indication (2021-2034)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.7.2. Market Revenue and Forecast, by Service (2021-2034)

11.3.7.3. Market Revenue and Forecast, by Indication (2021-2034)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.2. Market Revenue and Forecast, by Service (2021-2034)

11.4.3. Market Revenue and Forecast, by Indication (2021-2034)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.4.2. Market Revenue and Forecast, by Service (2021-2034)

11.4.4.3. Market Revenue and Forecast, by Indication (2021-2034)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.5.2. Market Revenue and Forecast, by Service (2021-2034)

11.4.5.3. Market Revenue and Forecast, by Indication (2021-2034)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.6.2. Market Revenue and Forecast, by Service (2021-2034)

11.4.6.3. Market Revenue and Forecast, by Indication (2021-2034)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.7.2. Market Revenue and Forecast, by Service (2021-2034)

11.4.7.3. Market Revenue and Forecast, by Indication (2021-2034)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.5.2. Market Revenue and Forecast, by Service (2021-2034)

11.5.3. Market Revenue and Forecast, by Indication (2021-2034)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.5.4.2. Market Revenue and Forecast, by Service (2021-2034)

11.5.4.3. Market Revenue and Forecast, by Indication (2021-2034)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.5.5.2. Market Revenue and Forecast, by Service (2021-2034)

11.5.5.3. Market Revenue and Forecast, by Indication (2021-2034)

Chapter 12. Company Profiles

12.1. Fresenius SE & Co. KGaA

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. GE Healthcare

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Linde plc

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. F. Hoffmann-La Roche Ltd.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. A&D Company

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. BAYADA Home Health Care

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Invacare Corporation

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Abbott

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Amedisys

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. ResMed

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client